$0.14 EPS Expected for Manning and Napier (MN), Clough Capital Partners LP Upped Its Alder Biopharmaceuticals (ALDR) Position

June 30, 2017 - By Richard Conner

Clough Capital Partners LP increased Alder Biopharmaceuticals Inc (ALDR) stake by 168.6% reported in 2016Q4 SEC filing. Clough Capital Partners LP acquired 294,035 shares as Alder Biopharmaceuticals Inc (ALDR)’s stock declined 24.25%. The Clough Capital Partners LP holds 468,435 shares with $9.74 million value, up from 174,400 last quarter. Alder Biopharmaceuticals Inc now has $545.44 million valuation. The stock decreased 1.23% or $0.15 during the last trading session, reaching $12. About shares traded. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has declined 33.67% since June 30, 2016 and is downtrending. It has underperformed by 50.37% the S&P500.

Analysts expect Manning and Napier Inc (NYSE:MN) to report $0.14 EPS on July, 26.They anticipate $0.03 EPS change or 17.65% from last quarter’s $0.17 EPS. MN’s profit would be $2.16M giving it 7.86 P/E if the $0.14 EPS is correct. After having $0.13 EPS previously, Manning and Napier Inc’s analysts see 7.69% EPS growth. The stock increased 2.33% or $0.1 during the last trading session, reaching $4.4. About shares traded. Manning and Napier Inc (NYSE:MN) has declined 46.69% since June 30, 2016 and is downtrending. It has underperformed by 63.39% the S&P500.

Among 6 analysts covering Manning & Napier Advisors (NYSE:MN), 0 have Buy rating, 3 Sell and 3 Hold. Therefore 0 are positive. Manning & Napier Advisors had 14 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Manning and Napier Inc (NYSE:MN) earned “Mkt Perform” rating by Raymond James on Monday, September 14. On Wednesday, June 14 the stock rating was upgraded by Keefe Bruyette & Woods to “Mkt Perform”. The stock of Manning and Napier Inc (NYSE:MN) has “Neutral” rating given on Friday, July 15 by Credit Suisse. The firm earned “Market Perform” rating on Friday, October 14 by Wood. Wood maintained the stock with “Sell” rating in Tuesday, April 11 report. The stock of Manning and Napier Inc (NYSE:MN) earned “Neutral” rating by Credit Suisse on Monday, January 11. The stock has “Market Perform” rating by Wood on Thursday, September 3. The company was downgraded on Thursday, October 27 by Keefe Bruyette & Woods. JP Morgan maintained Manning and Napier Inc (NYSE:MN) rating on Tuesday, September 8. JP Morgan has “Underweight” rating and $8 target.

Investors sentiment decreased to 0.79 in Q4 2016. Its down 1.06, from 1.85 in 2016Q3. It is negative, as 13 investors sold Manning and Napier Inc shares while 34 reduced holdings. 17 funds opened positions while 20 raised stakes. 11.11 million shares or 1.83% less from 11.31 million shares in 2016Q3 were reported. Rmb Capital Mngmt Limited Liability Company, a Illinois-based fund reported 19,522 shares. Moreover, Advsrs Asset Management Inc has 0% invested in Manning and Napier Inc (NYSE:MN). Menta Ltd Co accumulated 122,997 shares or 0.08% of the stock. Deutsche State Bank Ag has invested 0% in Manning and Napier Inc (NYSE:MN). Brandes Inv Limited Partnership has invested 0% in Manning and Napier Inc (NYSE:MN). 4,636 are owned by Blackrock. Acadian Asset Management Ltd Llc reported 20,873 shares or 0% of all its holdings. Northern Tru owns 176,220 shares for 0% of their portfolio. Manufacturers Life Insur The holds 11,890 shares or 0% of its portfolio. 8,593 are owned by Intl Grp Incorporated. Citigroup Inc holds 0% or 22,242 shares. Creative Planning holds 0% in Manning and Napier Inc (NYSE:MN) or 450 shares. Wells Fargo And Mn reported 0% stake. Prudential Incorporated holds 0% or 20,746 shares. Blackrock Institutional Company Na holds 265,686 shares or 0% of its portfolio.

Manning & Napier, Inc. is an independent investment management company. The company has market cap of $67.82 million. The Firm operates through investment management industry segment. It has a 7.57 P/E ratio. It provides a range of investment solutions through separately managed accounts, mutual funds and collective investment trust funds, as well as a range of consultative services.

Among 11 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 10 have Buy rating, 1 Sell and 0 Hold. Therefore 91% are positive. Alder Biopharmaceuticals had 13 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was initiated by Piper Jaffray with “Overweight” on Monday, October 31. Credit Suisse maintained Alder Biopharmaceuticals Inc (NASDAQ:ALDR) rating on Tuesday, March 29. Credit Suisse has “Outperform” rating and $40 target. Jefferies initiated the shares of ALDR in report on Wednesday, September 9 with “Buy” rating. As per Thursday, April 21, the company rating was reinitiated by Wells Fargo. The company was initiated on Tuesday, September 13 by JP Morgan. The firm has “Buy” rating by Brean Capital given on Wednesday, April 20. The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) earned “Buy” rating by Jefferies on Wednesday, July 27.

Clough Capital Partners LP decreased Jpmorgan Chase & Co (NYSE:JPM) stake by 145,520 shares to 122,080 valued at $10.53 million in 2016Q4. It also reduced Pennymac Mtg Invt Tr (NYSE:PMT) stake by 283,400 shares and now owns 1.06 million shares. Ares Cap Corp (NASDAQ:ARCC) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.